BARCELONA (Reuters) – GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class. The two ... More »
(Reuters Health) – Women who exhibit many classic symptoms of post-traumatic stress disorder (PTSD) may be much more likely to develop ovarian cancer than their counterparts who don’t, a new study suggests. For the study, researchers asked women to identify th... More »
(Reuters) – GlaxoSmithKline said on Monday a late-stage study testing its initial maintenance therapy, Zejula, in patients with ovarian cancer who have undergone platinum-based chemotherapy showed positive results. Zejula, which belongs to a promising class of... More »
(Reuters) – Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients. The results showed the drug, Bavencio, in combination with, or as a follow-on treatment ... More »
A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble AstraZeneca’s ovarian cancer drug Lynparza slashed the risk of disease progression in a closely watched clinical trial, boosting its profile against rivals ... More »
